Audifás-Salvador Matus-Meza

Dr. Audifás-Salvador Matus-Meza

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2020 in Journal of Natural Products
Verified
Journal Article
Closed access
JDJose Antonio VELAZQUEZ DOMINGUEZ
Jose Antonio VELAZQUEZ DOMINGUEZ
VHVerónica Ivonne HernándezRamírez
Verónica Ivonne HernándezRamírez
Fernando CalzadaFernando Calzada
Fernando Calzada
Luis Varela-RodríguezLuis Varela-Rodríguez
Luis Varela-Rodríguez
DPDiana L. Pichardo-Hernández
Diana L. Pichardo-Hernández
Patricia Talamás-RohanaPatricia Talamás-Rohana
Patricia Talamás-Rohana

23 September 2024 in Molecules
Verified
Journal Article
Open access
PDF file
CVCitlali Vázquez
Citlali Vázquez
AMAudifás-Salvador Matus-Meza
Audifás-Salvador Matus-Meza
ONOswaldo Nuñez-Moreno
Oswaldo Nuñez-Moreno
BBBrenda Michelle Barbosa-Sánchez
Brenda Michelle Barbosa-Sánchez
VFVictor Manuel Farías-Gutiérrez
Victor Manuel Farías-Gutiérrez
ESEmma Saavedra
Emma Saavedra
Trypanosoma cruzi is a protozoan parasite that causes Chagas disease in humans. The current antichagasic drugs nifurtimox and benznidazole have inconveniences of toxicity; therefore, the search for alternative therapeutic strategies is necessary. The present study reports the synthesis, drug-likeness predictions, and in vitro anti-trypanosome activity of a series of 14 quinazoline 2,4,6-triamine derivatives. All compounds were tested against T. cruzi (epimastigotes and trypomastigotes) and in HFF1 human foreskin fibroblasts. The bioassays showed that compounds 2–4 containing nitrobenzoyl substituents at 6-position of the quinazoline 2,4,6-triamine nucleus were the most potent on its antiprotozoal activity. The effect was observed at 24 h and it was preserved for at least 5 days. Also, compounds 2–4 were not toxic to the human control cells, showing high selectivity index. The quinazoline nitro derivatives have potential use as antichagasic agents.

25 August 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
VHVerónica Ivonne HernándezRamírez
Verónica Ivonne HernándezRamírez
AMAudifás-Salvador Matus-Meza
Audifás-Salvador Matus-Meza
Norma Angélica OviedoNorma Angélica Oviedo
Norma Angélica Oviedo
MMMarco Antonio Magos-Castro
Marco Antonio Magos-Castro
JOJuan Carlos Osorio-Trujillo
Juan Carlos Osorio-Trujillo
Patricia Talamás-RohanaPatricia Talamás-Rohana
Patricia Talamás-Rohana
Recently, we published that the monoclonal antibody (D12 mAb) recognizes gp63 of L. mexicana, and it is responsible for COX activity. This D12 mAb exhibited cross-reactivity with Trypanosoma cruzi, Entamoeba histolytica, Acanthamoeba castellanii, and Naegleria fowleri. COX activity assays performed in these parasites suggested the potential presence of such enzymatic activity. In our investigation, we confirmed that wild-type recombinant gp63 exhibits COX-like activity, in contrast to a mutated recombinant gp63 variant. Consequently, our objective was to identify sequences orthologous to gp63 and subsequently analyze the binding of arachidonic acid (AA) to the putative active sites of these proteins. Given the absence of a crystallized structure for this protein in the Protein Data Bank (PDB), it was imperative to first obtain a three-dimensional structure by homology modeling, using leishmanolysin from Leishmania major (PDB ID: LML1) as a template in the Swiss model database. The results obtained through molecular docking simulations revealed the primary interactions of AA close to the Zinc atom present in the catalytic site of gp63-like molecules of several parasites, predominantly mediated by hydrogen bonds with HIS264, HIS268 and HIS334. Furthermore, COX activity was evaluated in commensal species such as E. dispar and during the encystment process of E. invadens.